Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
BLTE Catalyst Timeline
Dated clinical, regulatory and corporate events for Belite Bio, Inc
Catalyst Timeline
Dated clinical, regulatory & corporate events for Belite Bio, Inc
Upcoming catalysts 2
Event history 50
Past FDA Catalysts and PDUFA Decisions
How BLTE actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-10 | Tinlarebant (LBS-008) | Phase 3 data presentation | Phase 3 |
Drug Pipeline Intelligence
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Tinlarebant Small MoleculesNCT06388083 | STGD1 | Phase 2/3 | ACTIVE NOT_RECRUITING | 60 | Feb 1, 2028 | ||||||
| Tinlarebant Small MoleculesNCT05949593 | Geographic Atrophy | Phase 3 | ACTIVE NOT_RECRUITING | 429 | Aug 31, 2027 | ||||||
| Tinlarebant Small MoleculesCompletedNCT05244304 | Stargardt Disease 1 | Phase 3 | COMPLETED | 104 | Sep 11, 2025 | ||||||
| Tinlarebant Small MoleculesCompletedNCT05266014 | Stargardt Disease | Phase 1/2 | COMPLETED | 13 | Aug 15, 2023 | ||||||
| Tinlarebant Small MoleculesCompletedNCT05667688 | Dry Age-related Macular Degeneration | Phase 1 | COMPLETED | 15 | Jan 18, 2023 | ||||||
| BPN-14967 Small MoleculesCompletedNCT04005807 | Undisclosed | Phase 1 | COMPLETED | 40 | Dec 20, 2019 | ||||||
| LBS-008 Small MoleculesCompletedNCT03735810 | Undisclosed | Phase 1 | COMPLETED | 71 | Sep 16, 2019 |
Clinical Trial Results
Readouts, endpoints and source filings for every BLTE program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| tinlarebant BreakthroughPriorityFast Track+2 | Stargardt disease type 1 | Phase 3 | 2026-05-15 | In the Phase 3 DRAGON trial, tinlarebant achieved a clinically meaningful 35.7% reduction in the growth rate of atrophic retinal lesions compared to placebo, demonstrating its potential efficacy in treating Stargardt disease type 1.Read More | Belite Bio Announces Oral Presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026)Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Scholl Hendrik PeterOfficer (Chief Medical Officer) | Sell | -500 14,000 held | $162.04 | 11/12/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BLTE
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Paradigm Biocapital Advisors LP | 3.9 % (8.3 %) | 193.96 M | 1.14 M | -7.36% ( -90.75 K) |
Ownership Trends
BLTE Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How BLTE ranks across every disease it competes in
BLTE News
Belite Bio Reports Unaudited Third Quarter 2026 Financial Results and Provides a Corporate Update
Belite Bio reported its third quarter 2026 financial results, highlighting the FDA's priority review of its NDA for tinlarebant in Stargardt disease type 1. The company also submitted applications in Japan and other countries. Despite a significant net loss of $30.3 million, Belite Bio is advancing its clinical trials and regulatory submissions.
Read more →Belite Bio to Host Webcast on November 12, 2026, to Discuss Third Quarter 2026 Financial Results
Belite Bio will host a webcast on November 12, 2026, to discuss its third quarter financial results and provide a business update. The company focuses on therapies for degenerative retinal diseases and has positive trial results for its lead candidate, tinlarebant. The webcast will be accessible via a provided link.
Read more →Belite Bio Announces Uplisting to the Nasdaq Global Select Market
Belite Bio has announced its uplisting to the Nasdaq Global Select Market, effective October 19, 2026. This transition signifies the company's compliance with higher financial standards and aims to enhance its visibility among institutional investors. The company is focused on developing treatments for degenerative retinal diseases, including Stargardt disease, with its lead candidate, tinlarebant, currently in advanced clinical trials.
Read more →Belite Bio Announces Multi-Market Submission of Marketing Authorization Applications Via the Access Consortium Pathway for Tinlarebant for the Treatment of Stargardt Disease Type 1
Belite Bio has submitted Marketing Authorization Applications for tinlarebant to treat Stargardt Disease Type 1 in Singapore, the UK, and Switzerland. This submission, made through the Access Consortium, aims to expedite the approval process. If approved, tinlarebant will be the first treatment for this condition in these regions. The drug is also under review in the U.S. and Japan.
Read more →Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
Belite Bio, a clinical-stage drug development company, announced that it will present data at two upcoming medical conferences in Vienna, Austria. The presentations will focus on the company's lead candidate, Tinlarebant, which targets Stargardt disease. The drug has received various designations from the FDA, highlighting its potential in treating retinal diseases.
Read more →Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1
Belite Bio announced the submission of a New Drug Application for tinlarebant to treat Stargardt Disease Type 1 in Japan. This submission follows a similar application in the U.S. and aims to provide the first-ever treatment for this condition. Tinlarebant has received Sakigake designation, allowing for expedited review due to the significant unmet medical need.
Read more →Belite Bio to Participate in Four Upcoming Investor Conferences
Belite Bio, a clinical-stage drug development company, will participate in four investor conferences in September 2026. These events include the Wells Fargo Healthcare Conference, Cantor Global Healthcare Conference, Morgan Stanley Global Healthcare Conference, and H.C. Wainwright Investment Conference. The company aims to showcase its advancements in therapies for degenerative retinal diseases.
Read more →Belite Bio to Host Virtual Commercial Day on September 2, 2026
Belite Bio will host a Virtual Commercial Day on September 2, 2026, focusing on Stargardt disease type 1 (STGD1) and the potential of their drug tinlarebant. The event will feature experts in ophthalmology and discuss the unmet needs in STGD1 treatment. The FDA has accepted the New Drug Application for tinlarebant, with a Priority Review status and a Prescription Drug User Fee Act date set for February 12, 2027.
Read more →Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update
Belite Bio reported its second quarter 2026 financial results, highlighting the FDA's acceptance of the New Drug Application for tinlarebant for Stargardt disease type 1 with a Priority Review status. The company presented encouraging data from the Phase 3 DRAGON trial at the ASRS Annual Meeting. Despite a net loss of $28.4 million, Belite is preparing for the drug's potential launch and expansion of its commercial operations.
Read more →Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1
Belite Bio announced that the FDA accepted its New Drug Application for tinlarebant to treat Stargardt Disease Type 1. The agency granted Priority Review designation, setting a target action date of February 12, 2027. Clinical data showed a 35.7% reduction in the growth rate of atrophic retinal lesions compared to placebo. If approved, this would be the first treatment for this rare inherited retinal disease.
Read more →Belite Bio to Host Webcast on August 13, 2026, to Discuss Second Quarter 2026 Financial Results
Belite Bio, a clinical-stage drug development company, will host a webcast on August 13, 2026, to discuss its second-quarter financial results and provide a business update. The company focuses on therapeutics for degenerative retinal diseases, with its lead candidate, tinlarebant, currently in multiple trials. The webcast aims to inform stakeholders about the company's progress and financial health.
Read more →Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1
Belite Bio announced positive secondary endpoint data from its Phase 3 DRAGON trial of tinlarebant for Stargardt disease type 1 at the ASRS Annual Meeting. The treatment demonstrated a significant reduction in retinal lesion growth and stable qAF values compared to placebo. The company has completed its New Drug Application to the FDA for tinlarebant.
Read more →Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference
Belite Bio, Inc. will participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference on July 22, 2026. The company focuses on developing therapies for degenerative retinal diseases, including Stargardt disease and geographic atrophy. Their lead candidate, tinlarebant, has met primary endpoints in a Phase 3 trial and is undergoing further evaluation.
Read more →Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium
Belite Bio, a clinical-stage drug development company, will participate in the Piper Sandler Virtual Ophthalmology Investor Symposium on July 9, 2026. The company focuses on developing therapeutics for degenerative retinal diseases, including Stargardt disease and geographic atrophy. Their lead candidate, tinlarebant, has completed a Phase 3 trial and is currently undergoing further evaluations.
Read more →Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1
Belite Bio has completed the rolling submission of a New Drug Application for tinlarebant, an oral therapy aimed at treating Stargardt disease type 1. This submission, initiated under Breakthrough Therapy Designation, addresses a significant unmet medical need as there are currently no approved treatments for this rare retinal disease. The application will undergo a 60-day review by the FDA.
Read more →Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Belite Bio, a clinical-stage drug development company, will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026. The company focuses on developing therapeutics for degenerative retinal diseases and has made progress with its lead candidate, tinlarebant, which has met primary endpoints in clinical trials. The event will be accessible via webcast.
Read more →Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update
Belite Bio reported its unaudited financial results for Q1 2026, highlighting a rolling NDA submission for tinlarebant aimed at treating Stargardt disease type 1 (STGD1). The company has completed hiring for its commercial leadership team and has a strong cash position of $798.6 million. However, it also reported a net loss of $26.9 million, reflecting increased R&D expenses associated with clinical trials.
Read more →Belite Bio Receives Orphan Drug Status for Tinlarebant in Stargardt Disease in Switzerland
Belite Bio has received orphan drug status for its lead candidate, tinlarebant, for the treatment of Stargardt disease from Swissmedic. This designation follows the successful Phase 3 DRAGON trial, where tinlarebant achieved a 35.7% reduction in retinal lesion growth. The company is also progressing with a rolling NDA submission to the FDA, expected to complete by Q2 2026.
Read more →